Address: 14 Studencheskaya Street, 308007 Belgorod, Russia
Phone/fax: +7 4722 301859
Head of the Centre
Professor Mikhail Pokrovksy,
Doctor of Medicine
|
|
The BelSU Clinical and Preclinical Studies Centre was established as University鈥檚 structural department in 2011.
In 2011, the Centre entered the Federal Service on Surveillance in Healthcare鈥檚 list of organisations and institutions certified to conduct preclinical studies for medical drugs.
The Centre fulfils the requirements of the ISO 9001-2008 standard (certificate issued on 29.12.2011).
According to the Ministry of Public Health of the Russian Federation Decree No 274 of 27.04.2012, Belgorod State National Research University is accredited for conducting clinical studies.
Research team鈥檚 key accomplishments
The Centre has conducted over 50 preclinical studies on general toxic action, specific activity, pharmacokinetic properties and bioequivalence of medicinal drugs on order of large Russian and worldwide pharmaceutical companies, among them are the following:
- TEVA Pharmaceutical Industries LTD (Israel)
- Pharmstandard-Leksredstva, JSC (Kursk, Russia)
- Pharmstandard-Tomskhimpharm, JSC (Tomsk, Russia)
- Pharmstandard-UfaVita JSC (Ufa, Russia)
- Valenta Pharmaceuticals, JSC (Moscow, Russia)
- Pharmaceutical Company Obolensky, CJSC
- Akvion, CJSC
- Rafarma, CJSC
- R-Pharm, CJSC
- National Scientific Centre for Bioactive Substances Safety, OJSC
- N.F. Gamaleya Research Institute of Epidemiology and Microbiology
Research support
Much of the research funding at the Centre comes from the government, councils and funds:
- Russian Federation President Grant No 袦袣-905.2012.4
- Russian Federation President Grant No 袦袣-3136.2014.4
- Government Procurement Contract No 13411.1008799.13.129 of June, 27 2013 within the framework of 鈥淧harma 2020鈥� on 鈥淧reclinical studies on pharmaceutical drug based on small molecule the Arginase-2 inhibitors for treating arterial and pulmonary hypertension鈥�
- Government Procurement Contract No 13411.1008799.13.218 of December, 16 2013 within the framework of 鈥淧harma 2020鈥� on 鈥淧reclinical Studies of pharmaceutical pain management drug based on non-opioid analgesic TRPA-1 channel suppressor鈥�
- Government Assignment for conducting works for Ministry of 快猫视频 and Science of the Russian Federation (Government Procurement Contract No 4.913.2011)
- 3 grants from Foundation for Assistance to Small Innovative Enterprises in Science and Technology (FASIE / 校.袦.袧.袠.袣)
- a grant from Russian Foundation for Basic Research
The BelSU Clinical and Preclinical Studies Centre conducts research and development in most pressing problems of modern Experimental Pharmacology. Among main focuses of scientific effort of Centre鈥檚 laboratories are experimental Cardiac Pharmacology, Experimental Osteology, pharmacological correction of epithelial dysfunction during cardiovascular diseases, diabetes, gestational toxicosis and other nosologies, pharmacological correction of chronic limb ischemia, studying the possibilities for using distant pharmacological and ischemic preconditioning in surgery, obstetrics & gynaecology, and cardiology.
Based on research conducted, a detailed and comprehensive concept of the role of endothelium in course and regulation of a number of diseases. The Centre鈥檚 researcher formed approaches to pharmacological correction of endothelium-associated pathologies in cardiology, osteology, obstetrics & gynaecology. At present, the Centre鈥檚 staff together with scientists and researchers from Lomonosov Moscow State University and ChemRar High-Tech Centre applies joint effort to search and develop new molecules for aimed correction of endothelial dysfunction and pulmonary hypertension, as well as developing novel analgesics aimed at new biological target involved in noxious response.
All studies and research are conducted in partnership with Saint Ioasaph Belgorod Regional Clinical Hospital, the BelSU Medical and Preventive Clinic, Applied Immunomorphology and Cytogenetics Scientific and 快猫视频 Centre, Immunochemical Laboratory of regional anatomic pathology bureau.
The Centre鈥檚 research groups
- General Toxicology,
- Cardiac Pharmacology,
- Isolated Organ Pharmacology,
- Behavioral Pharmacology,
- Electrophysiology,
- Control Clinical Study,
- Pharmacokinetics.
General Toxicology research group conducts research into toxicological safety of pharmaceutical drugs. The research is conducted with due regard to latest standards of lab animals keeping and assessment of the influence of the pharmaceutical drugs under research on their life parameters.
Among research areas are:
- Acute toxicity
- Chronic toxicity
- Chronic toxicity in the immature animals
- Chronic maternal toxicity in animals
- Fertility research
- Allergic action
Cardiac Pharmacology research group works on research into CVS drugs pharmacological activity and searches for new remedies and ways for pharmacological correction of endothelium-derived pathology. Research is conducted by high-qualified staff on the Biopac System equipment (USA). Among their research focuses are:
- Antihypertensive action,
- Antidysrhythmic action,
- Cardioprotective action (coronary occlusion (heart attack),
- Endothelium protective action,
- Thrombolytic action,
- Factors, influencing neo-vasculogenesis,
Isolated Organ Pharmacology research group conducts studies:
- Ischemia/reperfusion-induced injury of Langendorf-perfused rat hearts,
- Mechanical activity in isolated segments of blood vessels (hepatic portal vein and aorta),
- Mechanical activity in isolated segments of intestinal wall,
- Mechanical activity in isolated uterine horn.
Behavioural Pharmacology research group covers entire spectrum of studies of pharmaceutical drugs influence on integrity of physiological responses:
Electrophysiology research group conducts the following kinds of research:
- Electrocardiogram tracing (ECG)
- Electroencephalography (EEG)
- Electromyography (EMG)
- Event-related potential (ERP)
- Impedance resistography.
Pharmacokinetics and Bioequivalence research group works on:
- Studying Pharmacokinetics of well-known pharmaceutical drugs and pharmacologically active compounds in experiment;
- Studying clinical pharmacokinetics of pharmaceutical drugs;
- Studying drug biotransformation and pharmacologically active compounds, identifying active metabolites;
- Biopharmaceutical research;
- Research on pharmacokinetics and pharmacodynamics;
- Drug interaction studies.
Prospects for the BelSU Clinical and Preclinical Studies Centre within the Belgorod Biopharmaceutical cluster
Clinical and Preclinical Studies Centre is a milestone for forming the infrastructure of the regional pharmaceutical cluster. The Centre provides facilities for studying effectiveness of various pharmaceutical drugs and their forms at cellular, organ and organism levels in laboratory animals.
Main ambitions of the BelSU Clinical and Preclinical Studies Centre are:
- to create at BelSU a scientific and educational infrastructure to
develop research into living systems pharmacology,
- to found a state-of-art preclinical translational research centre to
unite laboratories of pharmacokinetics, pharmacogenetics, cell technologies,
modern vivarium, and other divisions,
- to form an innovative scientific and educational environment to arrange
effective interaction and co-operation between the BelSU Clinical and
Preclinical Studies Centre and University鈥檚 departments, large local
pharmaceutical enterprises, smaller innovative enterprises of BelSU and
other universities,
- to coordinate live systems research aimed at identifying biomedical
targets and ways to affect them with drugs, composite medical materials,
devices and diagnostic systems,
- to integrate and promote such research projects to the Medicine of the
Future technology platform 鈥� live systems research development is an issue
of pressing importance for prevention, diagnosis and disease treatment,
using newest scientific approaches: genome sequencing, molecule- and
cellular-level therapeutic interventions; model building in silico (Bioinformatics),
microelectronics鈥損harma鈥揵iotechnology; technology convergence (bio-nano-info),
- to set an innovative scientific and educational environment providing
for effective co-operation between modern biomedical and pharmaceutical
technologies for development and production liquid, solid, and semisolid
dosage forms of drugs,
- to develop the University鈥檚 information resources and employ them for
pharmaceutical market research and analysis, elaboration of marketing plans,
promotion of import-substituting innovative pharmaceutical drugs, composite
materials, medical devices, diagnosticums, etc.
- to ensure effective and efficient use of scientific and technological
equipment through creating common use centres, integrating university鈥檚 own
and other universities鈥� possibilities for consolidating with production,
scientific, engineering and technological laboratories in order to optimize
the live systems and drug discovery developments,
- in cooperation with chairs and departments of the BelSU Institute of
Medicine, to conduct joint experimental and clinical research into employing
methods of regenerative cell treatment, cell immunotherapy, and into using
cell technology products for disease prevention and treatment:
- post-infarct heart failure,
- cardiac muscle and limb soft tissues ischemia resulting from systemic atherosclerosis - and inflammation of blood vessels,
- cancerous diseases,
- severe injuries or traumas to skeleton and soft tissues,
- traumatic and ischemic injuries to the central nervous system, including birth traumas and infantile cerebral paralysis (ICP),
- liver failure caused by hepatitides and cirrhosis of different origin,
- autoimmune and allergenic diseases,
- congenital diseases and genetic disorders.
- in cooperation with the BelSU Faculty of Biology and Chemistry, to discover and prepare for production growth mediums for cell, tissue and organ culture for import substitution and commercialization of original techniques,
- in cooperation with the BelSU Faculty of Pharmacy, to develop and study nanoparticulated drug formulations for pharmacologic follow-up of cell treatment (hyaluronidase, colonie-stimulating factor, endothelial growth factor, fibroblast growth factor, etc.).
Information was given by Mikhail Pokrovksy,
Head of the Clinical and Preclinical Studies Centre,
on 31.01.2017
Back to the section
Did you find a bug? Select a text fragment and press Ctrl+Enter.
The error message will be automatically sent to the editor.
